Jill Folkert, NP
Acute Care · San Antonio, TXNPI 1548504707
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sobi, Inc accounts for 79.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $4,005 and has fallen 95.9% since, to $162 in 2025. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $168.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$7K
- G1 Therapeutics, Inc.$218
- Adaptive Biotechnologies Corporation$173
- E.r. Squibb & Sons, L.L.C.$149
- Genentech, Inc.$146
- AstraZeneca$133
- plus $932 from 18 others
What the payments were for
- Speaking & faculty fees$4,23050%
- Travel & lodging$1,99524%
- Food & beverage$2,12725%
- Education$781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 17 | $6,679 |
| G1 Therapeutics, Inc. | 2 | $218 |
| Adaptive Biotechnologies Corporation | 3 | $173 |
| E.r. Squibb & Sons, L.L.C. | 2 | $149 |
| Genentech, Inc. | 1 | $146 |
| AstraZeneca | 4 | $133 |
| Immunogen, Inc. | 1 | $129 |
| Myriad Genetic Laboratories, Inc. | 1 | $122 |
| Karyopharm Therapeutics Inc. | 1 | $116 |
| Gilead | 2 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $78 |
| Bristol Myers Squibb | 2 | $43 |
| Pfizer | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| AbbVie | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| Seagen Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Merck | 1 | $18 |
| Amgen | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,430 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Warfarin Sodium | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other acute care in San Antonio
- Christie MorrisonSan Antonio$225K
- Jessica BjerkSan Antonio$20K
- Tara CummingSan Antonio$12K
- Erin HernandezSan Antonio$10K
- Daniel ChristensenSan Antonio$8K
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.